编辑先生: 正如Moynihan等人所述,制药业与其他行业一起参与了给疾病下定义的事情。制药业与批准新药的管理机构需要制定出准确、严谨的定义,以便能够正确地监测新药的安全性和效果。 实际上,按照Ebrahim,Bonaccorso和Sturchio所说的,现在更需要医药化。西方世界对药品的担忧导致了指南的出台,这件事说明“有太多的严重疾病没有能够得到准确的诊断和有效的治疗”。也正是制药业准确地指出了循证 Editor: As Moynihan et al. Described, the pharmaceutical industry is involved with other industries in defining what is disease. The pharmaceutical industry and the authorities that approve new drugs need to have accurate and rigorous definitions in order to be able to properly monitor the safety and efficacy of new drugs. In fact, according to Ebrahim, Bonaccorso and Sturchio, it is even more medically needed. Concerns over drugs in the Western world led to the introduction of the guidelines, which shows that “there are too many serious illnesses that can not be accurately diagnosed and effectively treated.” It is precisely the pharmaceutical industry that points out evidence-based